Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
September 22, 2022 09:30 ET
|
Biomea Fusion, Inc.
Treatment with BMF-219 led to an increase in beta cell mass in ex-vivo experiments with human donor isletsBMF-219 showed improved pancreatic beta-cell function and beta cell area, insulin sensitivity,...
Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes
September 20, 2022 07:30 ET
|
Biomea Fusion, Inc.
Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in a preclinical animal model, driving an...
Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting
August 26, 2022 08:30 ET
|
Biomea Fusion, Inc.
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple...
Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights
August 01, 2022 16:05 ET
|
Biomea Fusion, Inc.
Continued to make significant progress advancing BMF-219, the company’s lead investigational orally administered covalent menin inhibitor, in multiple oncology indications COVALENT-101 (Phase I) study...
Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes
July 01, 2022 08:30 ET
|
Biomea Fusion, Inc.
Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater...
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
June 22, 2022 08:30 ET
|
Biomea Fusion, Inc.
BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM)Patients with R/R MM and R/R diffuse large B-cell...
Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
June 04, 2022 11:00 ET
|
Biomea Fusion, Inc.
Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose...
Biomea Fusion to Participate in Jefferies Healthcare Conference
June 02, 2022 18:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small...
Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022
June 01, 2022 08:30 ET
|
Biomea Fusion, Inc.
Company to host virtual investor R&D event on Monday, June 6, 2022 at 4:05 PM EDT featuring covalent menin inhibitor, BMF-219, as a potential novel treatment for type 2 diabetes REDWOOD CITY,...
Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022
May 26, 2022 18:30 ET
|
Biomea Fusion, Inc.
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLLBMF-219, a covalent menin inhibitor, demonstrated potency across ex...